

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 2 of 16

Docket No.: 61113(50370)

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Currently amended)** A mutant mammalian G protein-coupled receptor having an amino acid sequence which differs from a wild type G protein-coupled receptor having a wild type amino acid sequence comprising an amino acid motif (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>) closer to the C-terminal end than the N-terminal end of said wild type amino acid sequence, wherein the wild-type receptor is selected from the group consisting of the chemokine  $\alpha$  family of receptors and wherein:

X<sub>1</sub> denotes an amino acid residue at position 1 of said motif and is selected from the group consisting of Phe, Leu, Val, and Tyr;

X<sub>2</sub> denotes an amino acid residue at position 2 of said motif and is selected from the group consisting of Phe, Lys and Gln;

X<sub>3</sub> denotes an amino acid residue at position 3 of said motif and is selected from the group consisting of Leu, Arg, Glu, Asn, Gln, Ser, Ala, Leu ; and

X<sub>4</sub> denotes an amino acid residue at position 4 of said motif and is selected from the group consisting of Ala, Cys, Asp, Glu, Gly, Ser, Thr and Tyr; and

wherein said mutant receptor comprises a seventh transmembrane domain with a carboxy terminal end;

at least one ~~point~~ amino acid mutation at a position in said amino acid motif;

wherein upon interaction with a ligand to modulate a signal transduction pathway in a cell, a signal generated by said mutant receptor is greater than a signal generated upon interaction of said ligand with a wild type G protein-coupled receptor.

2. **(Original)** The receptor of claim 1, wherein said cell is a yeast cell.

3. **(Original)** The receptor of claim 2, wherein said receptor acts as a surrogate for an endogenous yeast pheromone receptor in a pheromone response pathway of said cell.

4. **(Original)** The receptor of claim 2, wherein said cell belongs to the species *Saccharomyces cerevisiae*.

5. **(Original)** The receptor of claim 1, wherein said cell is a mammalian cell.

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 3 of 16

Docket No.: 61113(50370)

6. **(Currently amended)** The receptor of claim 1, wherein said receptor containing said amino acid motif with no point-mutation thereon generates no detectable signal.

7. **(Currently amended)** The receptor of claim 1, wherein said point-mutation comprises mutagenization at position 4 of said amino acid motif to Arg or to Lys.

8. **(Previously Presented)** The receptor of claim 1, wherein said wild type G protein- coupled receptor is IL8A receptor.

9. **(Original)** The receptor of claim 8, wherein said point-mutation is selected from the group consisting of : Arg to Trp at position 73, Met to Ile at position 246; and Gly to Arg at position 320.

10. **(Original)** The receptor of claim 8, wherein said ligand is interleukin 8 (IL8) or melanoma growth-stimulating activity-alpha (MGSΑ/GROα).

11. **(Previously Presented)** The receptor of claim 1, wherein said wild type G protein- coupled receptor is a human receptor.

12. **(Cancelled)**

13. **(Cancelled)**

14. **(Previously Presented)** The receptor of claim 52, comprising an amino acid sequence LAYSNSSVNPIYAFLSEN(FRKR)YKQV (SEQ ID NO:1) wherein said mutant amino acid motif within said sequence is (FRKR) (SEQ ID NO:2).

43. **(Previously Presented)** The receptor of claim 1, wherein said wild type G protein coupled receptor is a member of the rhodopsin family of receptors.

44. **(Currently amended)** A mutant mammalian IL8A receptor having an amino acid sequence which differs from a wild type IL8A receptor having a wild type amino acid sequence comprising an amino acid motif (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>) proximal to the carboxy terminal end of said wild type amino acid sequence, wherein:

621429

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 4 of 16

Docket No.: 61113(50370)

X<sub>1</sub> denotes an amino acid residue at position 1 of said motif and is selected from the group consisting of Phe, Leu, Val, and Tyr;  
X<sub>2</sub> denotes an amino acid residue at position 2 of said motif and is selected from the group consisting of Phe, Lys and Gln;  
X<sub>3</sub> denotes an amino acid residue at position 3 of said motif and is selected from the group consisting of Leu, Arg, Glu, Asn, Gln, Ser, Ala, Leu ; and  
X<sub>4</sub> denotes an amino acid residue at position 4 of said motif and is selected from the group consisting of Ala, Cys, Asp, Glu, Gly, Ser, Thr and Tyr, and  
wherein said mutant receptor comprises a seventh transmembrane domain with a carboxy terminal end; and

at least one ~~point~~ amino acid mutation at a position in said amino acid motif, wherein said ~~point~~ mutation is selected from the group consisting of: Arg to Trp at position 73, Met to Ile at position 246, and Gly to Arg at position 320, wherein upon interaction with a ligand to modulate a signal transduction pathway in a cell, a signal generated by said mutant receptor is greater than a signal generated upon interaction of said ligand with a wild type IL8A receptor.

45. (Previously Presented) The receptor of claim 44, wherein said cell is a yeast cell.
46. (Previously Presented) The receptor of claim 45, wherein said receptor acts as a surrogate for an endogenous yeast pheromone receptor in a pheromone response pathway of said cell.
47. (Previously Presented) The receptor of claim 45, wherein said cell belongs to the species *Saccharomyces cerevisiae*.
48. (Previously Presented) The receptor of claim 44, wherein said cell is a mammalian cell.
49. (Currently amended) The receptor of claim 44, wherein said receptor containing said amino acid motif with no ~~point~~ mutation therein generates no detectable signal.
50. (Currently amended) The receptor of claim 44, wherein said ~~point~~ mutation comprises mutagenization at position 4 of said amino acid motif to Arg or to Lys.

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 5 of 16

Docket No.: 61113(50370)

51. **(Previously Presented)** The receptor of claim 44, wherein said ligand is interleukin 8 (IL8) or melanoma growth-stimulating activity-alpha (MGSA/GRO $\alpha$ ).

52. **(Currently amended)** A mutant galanin receptor-1 having an amino acid sequence which differs from a wild type galanin receptor-1 having a wild type amino acid sequence comprising an amino acid motif (X<sub>1</sub>X<sub>2</sub>X<sub>3</sub>X<sub>4</sub>) proximal to the carboxy terminal end of said wild type amino acid sequence, wherein:

X<sub>1</sub> denotes an amino acid residue at position 1 of said motif and is selected from the group consisting of Phe, Leu, Val, and Tyr;

X<sub>2</sub> denotes an amino acid residue at position 2 of said motif and is selected from the group consisting of Phe, Lys and Gln;

X<sub>3</sub> denotes an amino acid residue at position 3 of said motif and is selected from the group consisting of Leu, Arg, Glu, Asn, Gln, Ser, Ala, I.eu ; and

X<sub>4</sub> denotes an amino acid residue at position 4 of said motif and is selected from the group consisting of Ala, Cys, Asp, Glu, Gly, Ser, Thr and Tyr; and

wherein said mutant receptor comprises a seventh transmembrane domain with a carboxy terminal end; and

at least one ~~point~~amino acid-mutation in said amino acid motif comprising Gly to Ala at position 320, wherein upon interaction with a ligand to modulate a signal transduction pathway in a cell, a signal generated by said mutant receptor is greater than a signal generated upon interaction of said ligand with a wild type galanin receptor-1.

53. **(Previously Presented)** The amino acid motif of claim 52, wherein X<sub>1</sub> denotes an amino acid residue at position 1 of said motif and is Phe;

X<sub>2</sub> denotes an amino acid residue at position 2 of said motif and is selected from the group consisting of Arg;

X<sub>3</sub> denotes an amino acid residue at position 3 of said motif and is selected from the group consisting of Lys; and

X<sub>4</sub> denotes an amino acid residue at position 4 of said motif and is Ala, Cys, Asp, Glu, Gly, Ser, Thr and Tyr.

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 6 of 16

Docket No.: 61113(50370)

54. **(Previously Presented)** The receptor of claim 52 or 53, wherein said cell is a yeast cell.

55. **(Previously Presented)** The receptor of claim 54, wherein said receptor acts as a surrogate for an endogenous yeast pheromone receptor in a pheromone response pathway of said cell.

56. **(Previously Presented)** The receptor of claim 54, wherein said cell belongs to the species *Saccharomyces cerevisiae*.

57. **(Previously Presented)** The receptor of claim 52 or 53, wherein said cell is a mammalian cell.

58. **(Previously Presented)** The receptor of claim 52 or 53, wherein said receptor containing said amino acid motif with no point-mutation therein generates no detectable signal.

59. **(Previously Presented)** The receptor of claim 52 or 53, wherein said receptor comprises mutagenization at position 4 of said amino acid motif to Arg or to Lys.

60. **(Cancelled)**

61. **(Previously Presented)** The mutant mammalian G protein-coupled receptor of claim 1, wherein said amino acid motif commences 5-10 acid residues from the carboxy terminal end of said wild type amino acid sequence.

62. **(Previously Presented)** The mutant mammalian G protein-coupled receptor of claim 44, wherein said amino acid motif commences 5-10 acid residues from the carboxy terminal end of said wild type amino acid sequence.

63. **(Previously Presented)** The mutant mammalian G protein-coupled receptor of claim 52, wherein said amino acid motif commences 5-10 acid residues from the carboxy terminal end of said wild type amino acid sequence.

Application No. 09/362,286  
Amendment dated December 19, 2005  
Reply to Office Action of September 19, 2005  
Page 7 of 16

Docket No.: 61113(50370)

64. (Cancelled)

65. (Cancelled)

66. (Cancelled)

67. (Previously Presented) The receptor of claim 44, comprising an amino acid sequence LGFLHSCLNPIIYAFIGQN[FRNG]FLKM (SEQ ID NO:3) wherein said mutant amino acid motif within said sequence is (FRKG) (SEQ ID NO:4).

68. (Previously Presented) The receptor of claim 1, wherein the chemokine  $\alpha$  receptor is selected from the group consisting of receptors for IL-8, melanoma growth-stimulating activity (MGSA/GRO), platelet factor 4 (PF-4),  $\beta$  thromboglobulin ( $\beta$ TG), IP-10, and FNA-78.